What if next generation sequencing could help us diagnose mysterious infectious illnesses?
More about Charles
Infectious disease physician and clinical microbiologist Charles Chiu is the director of the University of California, San Francisco (UCSF)-Abbott Viral Diagnostics and Discovery Center, a translational research laboratory engaged in the development and validation of next-generation sequencing assays, pathogen discovery, bioinformatics software design, nanopore sequencing, and characterization of emerging infections (such as Lyme disease, enterovirus D68, and Zika virus). Next-generation sequencing can dramatically reduce the time necessary for clinical diagnosis of infections from rare, novel, or unexpected pathogens − including viruses, bacteria, fungi, and parasites, and its emergence heralds a new era in infectious disease diagnostics. Charles has authored more than 60 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory board for Therabio, Karius, and Rubicon Genomics.